

## Cytotoxicological Evaluation of a Folate Receptor Targeting Drug Delivery System Based on Cyclodextrins

**Authors :** Caroline Mendes, Mary McNamara, Orla Howe

**Abstract :** For chemotherapy, a drug delivery system should be able to specifically target cancer cells and deliver the therapeutic dose without affecting normal cells. Folate receptors (FR) can be considered key targets since they are commonly over-expressed in cancer cells and they are the molecular marker used in this study. Here, cyclodextrin (CD) has been studied as a vehicle for delivering the chemotherapeutic drug, methotrexate (MTX). CDs have the ability to form inclusion complexes, in which molecules of suitable dimensions are included within the CD cavity. In this study,  $\beta$ -CD has been modified using folic acid so as to specifically target the FR molecular marker. Thus, the system studied here for drug delivery consists of  $\beta$ -CD, folic acid and MTX (CDEnFA:MTX). Cellular uptake of folic acid is mediated with high affinity by folate receptors while the cellular uptake of antifolates, such as MTX, is mediated with high affinity by the reduced folate carriers (RFCs). This study addresses the gene (mRNA) and protein expression levels of FRs and RFCs in the cancer cell lines CaCo-2, SKOV-3, HeLa, MCF-7, A549 and the normal cell line BEAS-2B, quantified by real-time polymerase chain reaction (real-time PCR) and flow cytometry, respectively. From that, four cell lines with different levels of FRs, were chosen for cytotoxicity assays of MTX and CDEnFA:MTX using the MTT assay. Real-time PCR and flow cytometry data demonstrated that all cell lines ubiquitously express moderate levels of RFC. These experiments have also shown that levels of FR protein in CaCo-2 cells are high, while levels in SKOV-3, HeLa and MCF-7 cells are moderate. A549 and BEAS-2B cells express low levels of FR protein. FRs are highly expressed in all the cancer cell lines analysed when compared to the normal cell line BEAS-2B. The cell lines CaCo-2, MCF-7, A549 and BEAS-2B were used in the cell viability assays. 48 hours treatment with the free drug and the complex resulted in IC<sub>50</sub> values of  $93.9 \mu\text{M} \pm 9.2$  and  $56.0 \mu\text{M} \pm 4.0$  for CaCo-2 for free MTX and CDEnFA:MTX respectively,  $118.2 \mu\text{M} \pm 10.8$  and  $97.8 \mu\text{M} \pm 12.3$  for MCF-7,  $36.4 \mu\text{M} \pm 6.9$  and  $75.0 \mu\text{M} \pm 8.5$  for A549 and  $132.6 \mu\text{M} \pm 12.1$  and  $288.1 \mu\text{M} \pm 16.3$  for BEAS-2B. These results demonstrate that MTX is more toxic towards cell lines expressing low levels of FR, such as the BEAS-2B. More importantly, these results demonstrate that the inclusion complex CDEnFA:MTX showed greater cytotoxicity than the free drug towards the high FR expressing CaCo-2 cells, indicating that it has potential to target this receptor, enhancing the specificity and the efficiency of the drug.

**Keywords :** cyclodextrins, cancer treatment, drug delivery, folate receptors, reduced folate carriers

**Conference Title :** ICTDDS 2017 : International Conference on Targeted Drug Delivery System

**Conference Location :** Paris, France

**Conference Dates :** January 23-24, 2017